Search Results - "Csermak, Katalin"

Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019 by Oshagbemi, Olorunfemi A, Lopez-Romero, Pedro, Winnips, Cornelis, Csermak, Katalin R, Su, Guoqin, Aubrun, Elodie

“…Children in sub-Saharan Africa (SSA) remain the most vulnerable to malaria and malaria mortality. This study estimated the disease burden and distribution of…”
Get full text

The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound by Bouwman, Suzan AM, Zoleko-Manego, Rella, Renner, Katalin Csermak, Schmitt, Esther K., Mombo-Ngoma, Ghyslain, Grobusch, Martin P.

“…Cipargamin (KAE609) is a novel spiroindolone class drug for the treatment of malaria, currently undergoing phase 2 clinical development. This review provides…”
Get full text

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa by Ndayisaba, Gilles, Yeka, Adoke, Asante, Kwaku Poku, Grobusch, Martin P, Karita, Etienne, Mugerwa, Henry, Asiimwe, Stephen, Oduro, Abraham, Fofana, Bakary, Doumbia, Seydou, Jain, Jay Prakash, Barsainya, Sarita, Kullak-Ublick, Gerd A, Su, Guoqin, Schmitt, Esther K, Csermak, Katalin, Gandhi, Preetam, Hughes, David

“…The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations…”
Get full text

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria by Schmitt, Esther K, Ndayisaba, Gilles, Yeka, Adoke, Asante, Kwaku Poku, Grobusch, Martin P, Karita, Etienne, Mugerwa, Henry, Asiimwe, Stephen, Oduro, Abraham, Fofana, Bakary, Doumbia, Seydou, Su, Guoqin, Csermak Renner, Katalin, Venishetty, Vinay Kumar, Sayyed, Sarfaraz, Straimer, Judith, Demin, Ivan, Barsainya, Sarita, Boulton, Caroline, Gandhi, Preetam

“…Abstract Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis…”
Get full text

Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006 by Weitzman, Richard, Sauter, Nicholas, Eriksen, Erik Fink, Tarassoff, Peter G, Lacerna, Leo V, Dias, Rosh, Altmeyer, Anne, Csermak-Renner, Katalin, McGrath, Lynne, Lantwicki, Linda, Hohneker, John A

“…Abstract In light of recent reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include an intravenous bisphosphonate,…”
Get full text

High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine by Straimer, Judith, Gandhi, Preetam, Renner, Katalin Csermak, Schmitt, Esther K

“…Abstract In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with…”
Get full text

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial by Ogutu, Bernhards, Yeka, Adoke, Kusemererwa, Sylvia, Thompson, Ricardo, Tinto, Halidou, Toure, Andre Offianan, Uthaisin, Chirapong, Verma, Amar, Kibuuka, Afizi, Lingani, Moussa, Lourenço, Carlos, Mombo-Ngoma, Ghyslain, Nduba, Videlis, N'Guessan, Tiacoh Landry, Nassa, Guétawendé Job Wilfried, Nyantaro, Mary, Tina, Lucas Otieno, Singh, Piyoosh K, El Gaaloul, Myriam, Marrast, Anne Claire, Chikoto, Havana, Csermak, Katalin, Demin, Ivan, Mehta, Dheeraj, Pathan, Rashidkhan, Risterucci, Celine, Su, Guoqin, Winnips, Cornelis, Kaguthi, Grace, Fofana, Bakary, Grobusch, Martin Peter

“…Emergence of drug resistance demands novel antimalarial drugs with new mechanisms of action. We aimed to identify effective and well tolerated doses of…”
Get full text

Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study by Sangana, Ramachandra, Ogutu, Bernhards, Yeka, Adoke, Kusemererwa, Sylvia, Tinto, Halidou, Toure, Andre Offianan, Kibuuka, Afizi, Lingani, Moussa, Lourenço, Carlos, Mombo-Ngoma, Ghyslain, Nduba, Videlis, Landry N'Guessan, Tiacoh, Nassa, Guétawendé Job Wilfried, Nyantaro, Mary, Tina, Lucas Otieno, Anvikar, Anup, Sinha, Abhinav, Kaguthi, Grace, Fofana, Bakary, Grobusch, Martin Peter, Gaaloul, Myriam El, Marrast, Anne Claire, Pathan, Rashidkhan, Chikoto, Havana, Csermak, Katalin, Risterucci, Celine, Su, Guoqin, Winnips, Cornelis, Zhang, Jie, Zack, Julia

“…The novel antimalarial ganaplacide combined with lumefantrine solid dispersion formulation (LUM-SDF) was effective and well tolerated in the treatment of…”
Get full text

Avascular necrosis of the jaws: risk factors in metastatic cancer patients by Tarassoff, Peter, Csermak, Katalin

Get full text

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum by McCarthy, James S, Abd-Rahman, Azrin N, Collins, Katharine A, Marquart, Louise, Griffin, Paul, Kümmel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J Prakash, Gandhi, Preetam

“…The spiroindolone cipargamin, a new antimalarial compound that inhibits ATP4, is currently in clinical development. This study aimed to characterize the…”
Get full text

Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations by Chughlay, Mohamed Farouk, Akakpo, Samantha, Odedra, Anand, Csermak-Renner, Katalin, Djeriou, Elhadj, Winnips, Cornelis, Leboulleux, Didier, Gaur, Aditya H, Shanks, G Dennis, McCarthy, James, Chalon, Stephan

“…Malaria volunteer infection studies (VISs) accelerate new drug and vaccine development. In the induced blood-stage malaria (IBSM) model, volunteers are…”
Get full text

PKC412--a protein kinase inhibitor with a broad therapeutic potential by Fabbro, D, Ruetz, S, Bodis, S, Pruschy, M, Csermak, K, Man, A, Campochiaro, P, Wood, J, O'Reilly, T, Meyer, T

“…The staurosporine derivative PKC412 was originally identified as an inhibitor of protein kinase C (PKC) and subsequently shown to inhibit other kinases…”
Get more information

Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro by Ganeshaguru, K, Wickremasinghe, RG, Jones, DT, Gordon, M, Hart, SM, Virchis, AE, Prentice, HG, Hoffbrand, AV, Man, A, Champain, K, Csermak, K, Mehta, AB

“…Department of Hematology, Royal Free & University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK…”
Get full text

A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C by Virchis, Andres, Ganeshaguru, Kanagasabai, Hart, Steve, Jones, Dylan, Fletcher, Linda, Wright, Faith, Wickremasinghe, Ranmohan, Man, Anthony, Csermak, Katalin, Meyer, Thomas, Fabbro, Doriano, Champain, Kate, Yap, Alan, Prentice, H Grant, Mehta, Atul

“…PKC412 (formally CGP41251) selectively inhibits protein kinase C (PKC) isoforms and has been shown to be cytotoxic to malignant cells in vitro. We have…”
Get more information